Retrophin

Travere

Biotech

FDA sets back Travere's plans for kidney disease drug approval

The FDA has crushed Travere Therapeutics’ hopes of seeking accelerated approval in a rare kidney disorder on the strength of existing interim data.

Nick Paul Taylor May 26, 2021 8:10am

Eric Dube

Retrophin sheds Shkreli connection with new name: Travere

Nov 17, 2020 10:30am

money

Retrophin buys up Orphan Technologies for rare disease drug

Oct 23, 2020 8:18am

Chutes Ladders

Disarm Therapeutics brings on former Enzyvant boss as CEO

Jul 22, 2019 11:08am

shkreli

From prison, Shkreli sues—and settles with—Retrophin executives

Jun 21, 2019 10:33am

Parachute8

Chutes & Ladders—Cell Medica names Kite's European chief as CEO

Aug 3, 2018 9:43am